Managing Comorbidities in Psoriasis

Actas Dermo-Sifiliograficas

Volumn 100, Issue SUPPL. 2, 2009, Pages 22-27

  Boehncke, W H ^a   Boehncke, S ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

cardiovascular morbidity; comorbidities; psoriasis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERFERON; LEFLUNOMIDE; LITHIUM; METHOTREXATE; NON STEROIDAL ANTI RHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TERBINAFINE; TETRACYCLINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIAGNOSTIC PROCEDURE; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PSORIASIS; PSORIATIC ARTHRITIS; RISK FACTOR;

ARTHRITIS, PSORIATIC; HUMANS; PSORIASIS;

EID: 76749145599     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)73374-5     Document Type: Article

References (24)

1. Schön M.P., and Boehncke W.-H. Psoriasis. New Engl J Med 352 (2005) 1899-1912
2. Sabat R., Philipp S., Höflich C., Kreutzer S., Wallace E., Asadullah K., et al. Immunopathogenesis of psoriasis. Exp Dermatol 16 (2007) 779-798
3. Asadullah K., Volk H.-D., and Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 23 (2002) 47-53
4. Boehncke W.-H. Immunomodulatory drugs for psoriasis. Br Med J 327 (2003) 634-635
5. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., and Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005) 722-732
6. Popa C., Netea M.G., Radstake T., van der Meer J.W., Stalenhoef A.F., van Riel P.L., et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 303-305
7. Mattey D.L., Glossop J.R., Nixon N.B., and Dawes P.T. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthr Rheum 56 (2007) 3940-3948
8. Dixon W.G., Watson K.D., Lunt M., and Hyrich K.L. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy. Arthr Rheum 56 (2007) 2905-2912
9. Gottlieb A.B., Chao C., and Dann F. Psoriasis comorbidities. J Dermatol Treat 19 (2008) 5-21
10. Gladman D.D., Antoni C., Mease P., Clegg D.O., and Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 Suppl 2 (2005) ii14-ii17
11. Gladman D.D., Farewell V.T., and Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 22 (1995) 675-679
12. Soriano E.R., and McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33 (2006) 1422-1430
13. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., and On behalf of the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr Rheum 54 (2006) 2665-2673
14. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
15. Gelfand J.M., Troxel A.B., Lewis J.D., Kurd S.K., Shin D.B., Wang X., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143 (2007) 1493-1499
16. Mallbris L., Akre O., Granath F., Yin L., Lindelöf B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
17. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
18. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156 (2007) 271-276
19. Boehncke W.H., Bürger C., and Boehncke S. Co-morbidities in psoriasis vulgaris. Hautarzt 60 (2009) 116-121
20. Boehncke S., Thaci D., Beschmann H., Ludwig R.J., Ackermann H., Badenhoop K., et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 157 (2007) 1249-1251
21. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
22. Nast A., Kopp I., Augustin M., Banditt K.B., Boehncke W.-H., Follmann M., et al. German evidence-based guidelines for the treatment of psoriasis vulgaris. Arch Dermatol Res 299 (2007) 111-138
23. Gerdes S., Zahl V.A., Knopf H., Weichenthal M., and Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 159 (2008) 1116-1123
24. Kimball A.B., Gladman D.D., Gelfand J.M., Gordon K., Horn E.J., Korman N.J., et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58 (2008) 1031-1042